
Opinion|Videos|December 18, 2024
Available Treatment Options for PBC
Panelists discuss how ursodeoxycholic acid is the first-line treatment for primary biliary cholangitis (PBC), with early initiation being crucial for optimal outcomes and prevention of disease progression.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What options are available for the initial management of PBC?
Advertisement
Related to this article

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
5

